Company Information

Market
HKEX GEM
Listing Date
2005-09-12
Industry
Innovative Drugs & Biologics
Fiscal Year End
Dec 31
ISIN
CNE100000775

Industry

Innovative Drugs & Biologics 2.03%
124 stocks in this industry
Down 91 Up 17
Industry RankingsValue (HKD)Rank
Revenue (Last FY)1.14B51/112
Net Profit (Last FY)-47.91M63/125
ROE (Last FY)-6.29%61/117

Change is the 2026-11-13 close against the previous close; the industry change is the equal-weighted average of its stocks. Sub-industry classification is maintained by cibo. Last FY is each company's latest annual report. Net profit is profit attributable to owners of the parent; ROE = net profit / closing equity attributable to owners. Non-HKD statements are converted at ECB reference rates.

Management

NamePosition
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED Executive Director
张锋 Executive Director
黄剑波 Executive Director
张晓光 Executive Director
张翼飞 Non-Executive Director
金锐 Non-Executive Director
张晓鹏 Non-Executive Director
易永发 Independent Non-Executive Director
潘嘉阳 Independent Non-Executive Director
朱嘉敏 Independent Non-Executive Director

Board list from the HKEXnews "List of Directors and their Role and Function", as of 2026-06-25.

About this page

This page shows NEP INTERLONG (08329) company information, related securities, the price change distribution and in-industry rankings within its sub-industry, and the board of directors. Quotes come from HKEX Daily Quotations, financial metrics from each company's latest annual report, and the director list from HKEXnews.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect